Health ❯ Obesity

Weight Loss Treatments

GLP-1 Drugs Clinical Trials Pharmaceuticals GLP-1 Agonists Medications Prescription Drugs GLP-1 Receptor Agonists Drug Efficacy Wegovy GLP-1 Medications Semaglutide Clinical Research Drug Development Drug Treatments Injectable Therapies Anti-Obesity Drugs Pharmaceutical Interventions Pharmacological Treatments GLP-1 Hormones Patient Experiences GLP-1 Medicines Pharmaceutical Products Zepbound Medication Efficacy Market Penetration Injectable Drugs Medication Use GLP-1RA Medications Genetic Variants Pharmacotherapy

Viking Therapeutics Rallies as Weight‑Loss Program Moves Toward Late‑Stage Testing

Pivotal Phase 3 readouts for injectable and oral VK2735 are expected in 2027 and 2028.

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Eli Lilly Chooses Pennsylvania for $3.5 Billion Plant to Produce Weight-Loss Injectables

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Novo Nordisk Survey Finds Wegovy Users Report Sharp Drop in ‘Food Noise’

Semaglutide Curbs Cocaine Use and Relapse-Seeking in Rats, Peer-Reviewed Study Finds

Guidelines Tie Diet and Exercise to GLP-1 Drug Success as India Launches Treatments